## Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208(b)(3)

Steven Ebert, Pharm.D.

Committee:	Anti-Infective Drugs Advisory Committee			
<b>Meeting Date:</b>	March 6, 2006			
I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application (NDA) 21-572/S-008, Cubicin (daptomycin for injection 500 mg/vial), manufactured for Cubist Pharmaceuticals by Integrated Commercialization Solutions, for the proposed indication for the treatment of Staphylococcus aureus bacteremia, including those with known or suspected endocarditis caused by methicillin-susceptible and methicillin-resistant strains, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).				
<b>Type of Interest</b>		Nature		Magnitude
Speaker's Bureau		Sponsor		Less than \$10,001 per year.
Speaker's Bureau		Competitor		Less than \$10,001 per year.
Related Consulting		Competitor		Less than \$10,001 per year.
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.				
//S//				1/27/06
Signature of SGE			Date	